Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry

Meliga, Emanuele; Garcia-Garcia, Hector Manuel; Valgimigli, Marco; Chieffo, Alaide; Biondi-Zoccai, Giuseppe; Maree, Andrew O; Cook, Stephen; Reardon, Lindsay; Moretti, Claudio; De Servi, Stefano; Palacios, Igor F; Windecker, Stephen; Colombo, Antonio; van Domburg, Ron; Sheiban, Imad; Serruys, Patrick W (2008). Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. Journal of the American College of Cardiology, 51(23), pp. 2212-9. New York, N.Y.: Elsevier 10.1016/j.jacc.2008.03.020

Full text not available from this repository.

OBJECTIVES: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease. BACKGROUND: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained. METHODS: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years. RESULTS: Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovascular events (MACE)-free survival in the whole population was 73.5%. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2% of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2%, with mortality, reinfarction, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, respectively. In the emergent group the 3-year MACE-free survival was 68.2%, with mortality, reinfarction, TLR, and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively. CONCLUSIONS: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
UniBE Contributor:	Cook, Stéphane, Windecker, Stephan
ISSN:	0735-1097
ISBN:	18534266
Publisher:	Elsevier
Language:	English
Submitter:	Aline Kunz
Date Deposited:	04 Oct 2013 15:02
Last Modified:	05 Dec 2022 14:19
Publisher DOI:	10.1016/j.jacc.2008.03.020
PubMed ID:	18534266
Web of Science ID:	000256434200002
URI:	https://boris.unibe.ch/id/eprint/26937 (FactScience: 99156)